Anavex Life Sciences Corp.
NASDAQ: AVXL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher U. Missling
- Employees
- 42
- Headquarters
- New York City, United States
- IPO year
- 2006
- Market cap
- $237.2M
- Website
- https://www.anavex.com
Loading AVXL…
Loading profile data…Frequently asked questions about AVXL
What does Anavex Life Sciences Corp. (AVXL) do?
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric...
Where does AVXL trade?
Anavex Life Sciences Corp. (AVXL) trades on the NASDAQ Global Select.
What sector is AVXL in?
Anavex Life Sciences Corp. (AVXL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Anavex Life Sciences Corp.?
Christopher U. Missling is the chief executive officer of Anavex Life Sciences Corp. (AVXL).
Where is Anavex Life Sciences Corp. headquartered?
Anavex Life Sciences Corp. is headquartered in United States.
Does AVXL pay a dividend?
Anavex Life Sciences Corp. (AVXL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVXL go public?
Anavex Life Sciences Corp. (AVXL) completed its initial public offering in 2006.